Hibi Yatsuka, Ohye Tamae, Ogawa Kimio, Shimizu Yoshimi, Shibata Masahiro, Kagawa Chikara, Mizuno Yutaka, Uchino Shinya, Kosugi Shinji, Kurahashi Hiroki, Iwase Katsumi
Department of Endocrine Surgery, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan,
Surg Today. 2014 Nov;44(11):2195-200. doi: 10.1007/s00595-013-0826-8. Epub 2014 Jan 22.
We report a rare case with pheochromocytoma as the first manifestation of multiple endocrine neoplasia type 2A with RET mutation S891A. Bilateral pheochromocytomas were identified in a 54-year-old woman. Screening for RET revealed a rare S891A mutation located in the intracellular tyrosine kinase domain. This mutation was previously recognized as one of the mutations only in cases manifesting solely medullary thyroid carcinomas (MTCs). Since calcitonin stimulation test indicated positive result, total thyroidectomy was performed 1 year after the bilateral adrenalectomy, and C-cell hyperplasia was diagnosed by histopathological examination. Our report suggests that cases with S891A mutation, akin to those with other RET mutations, require screening for pheochromocytoma. In addition, it is indicated that calcitonin stimulation test should be performed even in the unaffected elder cases with S891A mutation although the mutation is classified as lowest risk group on MTC in guidelines.
我们报告了一例罕见病例,该病例中嗜铬细胞瘤是2A型多发性内分泌肿瘤伴RET基因S891A突变的首发表现。在一名54岁女性中发现了双侧嗜铬细胞瘤。对RET基因的筛查发现了一个位于细胞内酪氨酸激酶结构域的罕见S891A突变。该突变以前仅在仅表现为甲状腺髓样癌(MTC)的病例中被确认为突变之一。由于降钙素刺激试验结果呈阳性,在双侧肾上腺切除术后1年进行了全甲状腺切除术,组织病理学检查诊断为C细胞增生。我们的报告表明,与其他RET基因突变的病例一样,携带S891A突变的病例需要筛查嗜铬细胞瘤。此外,研究表明,即使是携带S891A突变的未受影响的老年病例,尽管该突变在指南中被归类为MTC的低风险组,也应进行降钙素刺激试验。